Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset
- PMID: 40296472
- PMCID: PMC12046197
- DOI: 10.7874/jao.2024.00493
Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset
Abstract
Background and objectives: Certain medications are associated with ototoxicity. This study assesses drug-induced ototoxicity in South Korea by analyzing the Korean national health data.
Subjects and methods: Hospital records of National Health Insurance members from 2009 to 2016 were reviewed. Data were compared between patients with and without hearing loss (HL). Individuals with HL were identified as having a primary diagnosis code for sensorineural HL or another type of HL in at least one outpatient or inpatient record according to the International Classification of Diseases-10.
Results: The members in the HL group increased slightly from 0.8% to 1.0% relative to the total sample, compared with 99.2% to 99.0% among the controls. The proportion of males in the HL group ranged from 45.6% to 47.6%, compared with 48.4% to 48.8% among the controls. The proportion of those aged ≥65 years in the HL group increased from 34.1% to 41.4%, compared with 10.6% to 13.3% among the controls. Hypertension prevalence (24.7%-25.7%) in the HL group was higher than that in the control group (12%-12.6%). Diabetes prevalence in the HL group was 10.6%-12.3%, compared with 4.4%-5.9% among the controls. The use of proton pump inhibitor components increased, particularly esomeprazole magnesium trihydrate and rabeprazole sodium, whereas the usage of pantoprazole sodium sesquihydrate and revaprazan was high initially but declined subsequently. The usage of painkillers such as acetaminophen, loxoprofen sodium, and ibuprofen remained high, and antibiotics such as cephalosporins indicated the highest usage. However, the use of penicillin antibiotics such as amoxicillin decreased significantly. Anticancer agents showed relatively low usage compared with other drug categories, whereas antihistamines showed extremely high usage across all years, with a continual increase.
Conclusions: These correlations and the underlying mechanisms necessitate further investigation, as several medicines have been linked to an increased risk of HL.
Keywords: Drug; Insights; National; Ototoxicity; South Korea.
Conflict of interest statement
The authors have no financial conflicts of interest.
Similar articles
-
Association of metabolic syndrome with the incidence of hearing loss: A national population-based study.PLoS One. 2019 Jul 26;14(7):e0220370. doi: 10.1371/journal.pone.0220370. eCollection 2019. PLoS One. 2019. PMID: 31348810 Free PMC article.
-
Review of Ototoxic Drugs Using Health Insurance Data: A Data-Driven Management System.OTO Open. 2025 Apr 25;9(2):e70121. doi: 10.1002/oto2.70121. eCollection 2025 Apr-Jun. OTO Open. 2025. PMID: 40291857 Free PMC article.
-
The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.Laryngoscope. 2020 Sep;130(9):E515-E521. doi: 10.1002/lary.28543. Epub 2020 Feb 17. Laryngoscope. 2020. PMID: 32065408
-
Early investigational drugs for hearing loss.Expert Opin Investig Drugs. 2015 Feb;24(2):201-17. doi: 10.1517/13543784.2015.960076. Epub 2014 Sep 22. Expert Opin Investig Drugs. 2015. PMID: 25243609 Free PMC article. Review.
-
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Cochrane Database Syst Rev. 2019 May 7;5(5):CD009219. doi: 10.1002/14651858.CD009219.pub5. Cochrane Database Syst Rev. 2019. PMID: 31063591 Free PMC article.
References
-
- Lee J, Fernandez K, Cunningham LL. Hear and now: ongoing clinical trials to prevent drug-induced hearing loss. Annu Rev Pharmacol Toxicol. 2024;64:211–30. - PubMed
-
- Yorgason JG, Fayad JN, Kalinec F. Understanding drug ototoxicity: molecular insights for prevention and clinical management. Expert Opin Drug Saf. 2006;5:383–99. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources